Algorithms, nomograms and the detection of indolent prostate cancerROOBOL, Monique J.World journal of urology (Print). 2008, Vol 26, Num 5, pp 423-429, issn 0724-4983, 7 p.Article

A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (Results of ERSPC, Rotterdam)ROOBOL, Monique J; SCHRÖDER, Fritz H; KRANSE, Ries et al.The Prostate. 2006, Vol 66, Num 6, pp 604-612, issn 0270-4137, 9 p.Article

Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?GOSSELAAR, Claartje; ROOBOL, Monique J; SCHRÖDER, Fritz H et al.BJU international (Papier). 2005, Vol 95, Num 2, pp 231-237, issn 1464-4096, 7 p.Article

Defining and predicting indolent and low risk prostate cancerBANGMA, Chris H; ROOBOL, Monique J.Critical reviews in oncology/hematology. 2012, Vol 83, Num 2, pp 235-241, issn 1040-8428, 7 p.Article

Long―term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) RotterdamLOEB, Stacy; XIAOYE ZHU; SCHRODER, Fritz H et al.BJU international (Papier). 2012, Vol 110, Num 11, pp 1678-1683, issn 1464-4096, 6 p.Article

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels <3.0 ng/ml? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPCSCHRÖDER, Fritz H; BANGMA, Chris H; ROOBOL, Monique J et al.European urology. 2008, Vol 53, Num 5, pp 901-908, issn 0302-2838, 8 p.Article

Interval cancers in prostate cancer screening : Comparing 2-and 4-year screening intervals in the european randomized study of screening for prostate cancer, gothenburg and rotterdamROOBOL, Monique J; GRENABO, Anna; SCHRÖDER, Fritz H et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 17, pp 1296-1303, issn 0027-8874, 8 p.Article

Biochemical progression rates in the screen arm compared to the control arm of the rotterdam section of the European Randomized study of Screening for Prostate Cancer (ERSPC)ROEMELING, Stijn; ROOBOL, Monique J; GOSSELAAR, Claartje et al.The Prostate. 2006, Vol 66, Num 10, pp 1076-1081, issn 0270-4137, 6 p.Article

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)ROOBOL, Monique J; ROOBOL, Dina W; SCHRÖDER, Fritz H et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 2, pp 343-346, issn 0090-4295, 4 p.Article

Epilogue: Different approaches for prostate cancer screening in the EU?SCHRÖDER, Fritz H; DENIS, Louis; ROOBOL, Monique J et al.European journal of cancer (1990). 2010, Vol 46, Num 17, pp 3120-3125, issn 0959-8049, 6 p.Article

Prostate Cancer Incidence and Disease-Specific Survival of Men with Initial Prostate-Specific Antigen Less Than 3.0 ng/ml Who Are Participating in ERSPC RotterdamBUL, Meelan; VAN LEEUWEN, Pim J; XIAOYE ZHU et al.European urology. 2011, Vol 59, Num 4, pp 498-505, issn 0302-2838, 8 p.Article

Screening for prostate cancer at low PSA range : The impact of digital rectal examination ontumor incidence and tumor characteristicsGOSSELAAR, Claartje; ROOBOL, Monique J; ROEMELING, Stijn et al.The Prostate. 2007, Vol 67, Num 2, pp 154-161, issn 0270-4137, 8 p.Article

Defining Increased Future Risk for Prostate Cancer : Evidence From a Population Based Screening Cohort. CommentarySCHRODER, Fritz H; ROOBOL, Monique J; ANDRIOLE, Gerald L et al.The Journal of urology. 2009, Vol 181, Num 1, pp 69-74, issn 0022-5347, 6 p.Article

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rateROOBOL, Monique J; KRANSE, Ries; VAN DER CRUIJSEN, Ingrid W et al.Urology (Ridgewood, NJ). 2002, Vol 59, Num 1, pp 91-96, issn 0090-4295Article

Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in Screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Commentary. Authors' replyWOLTERS, Tineke; ROOBOL, Monique J; BANGMA, Chris H et al.European urology. 2009, Vol 55, Num 2, pp 385-393, issn 0302-2838, 9 p.Article

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening programRAAIJMAKERS, René; KIRKELS, Wim J; ROOBOL, Monique J et al.Urology (Ridgewood, NJ). 2002, Vol 60, Num 5, pp 826-830, issn 0090-4295, 5 p.Article

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-upSCHRÖDER, Fritz H; HUGOSSON, Jonas; DENIS, Louis J et al.Lancet (British edition). 2014, Vol 384, Num 9959, pp 2027-2035, issn 0140-6736, 9 p.Article

Prostate Cancer Antigen 3: Diagnostic Outcomes in Men Presenting With Urinary Prostate Cancer Antigen 3 Scores ≥100SCHRÖDER, Fritz H; VENDERBOS, Lionne D. F; VAN DEN BERGH, Roderick C. N et al.Urology (Ridgewood, NJ). 2014, Vol 83, Num 3, pp 613-616, issn 0090-4295, 4 p.Article

Increased non-prostate cancer death risk in clinically diagnosed prostate cancerLEEUWEN, Pim J. Van; OTTO, Suzie J; KRANSE, Ries et al.BJU international (Papier). 2012, Vol 110, Num 2, pp 188-194, issn 1464-4096, 7 p.Article

Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance ProgramBUL, Meelan; VAN DEN BERGH, Roderick C. N; RANNIKKO, Antti et al.European urology. 2012, Vol 61, Num 2, pp 370-377, issn 0302-2838, 8 p.Article

Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational StudyBUL, Meelan; XIAOYE ZHU; RANNIKKO, Antti et al.European urology. 2012, Vol 62, Num 2, pp 195-200, issn 0302-2838, 6 p.Article

Sexual function with localized prostate cancer: active surveillance vs radical therapyVAN DEN BERGH, Roderick C. N; KORFAGE, Ida J; ROOBOL, Monique J et al.BJU international (Papier). 2012, Vol 110, Num 7, pp 1032-1039, issn 1464-4096, 8 p.Article

Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic TestROOBOL, Monique J; SCHRÖDER, Fritz H; VAN LEEUWEN, Pim et al.European urology. 2010, Vol 58, Num 4, pp 475-481, issn 0302-2838, 7 p.Article

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefitVAN LEEUWEN, Pim J; CONNOLLY, David; GAVIN, Anna et al.European journal of cancer (1990). 2010, Vol 46, Num 2, pp 377-383, issn 0959-8049, 7 p.Article

Does PSA velocity predict prostate cancer in pre-screened populations? CommentarySCHRÖDER, Fritz H; ROOBOL, Monique J; VAN DER KWAST, Theo H et al.European urology. 2006, Vol 49, Num 3, pp 460-465, issn 0302-2838, 6 p.Article